神经节苷脂对进展性脑卒中患者血浆S100βB的影响及其意义  

Effect of Ganglioside on Plasma S100β in Patients with Progressive Stroke and Prognostic Analysis

作　　者：李峥嵘[1] 杨欢[1] 

机构地区：[1]中南大学湘雅医院,湖南长沙410008

出　　处：《医学临床研究》2012年第9期1738-1740,共3页Journal of Clinical Research

摘　　要：【目的】探讨神经节苷脂对进展性脑卒中患者血浆S100β的影响及预后分析。【方法】对本院2011年1～12月收治的76例进展性脑卒中患者，随机分为治疗组以及对照组，对照组采用常规治疗，治疗组在对照组基础上给予其单唾液酸四已糖神经节苷脂钠进行治疗，比较两组血浆S100β水平、神经损伤评分及显效率。【结果】治疗组患者在接受治疗7d后其血浆S100β水平明显低于对照组（P〈0．05）；两组患者在治疗14d后神经损伤评分比较中具有统计学差异（P〈0．05）；治疗组患者治疗显效率80％明显高于对照组的69．44％，其差异有统计学意义（P〈0．05）。【结论】对进展性脑卒中患者采用单唾液酸四己糖神经节苷脂钠治疗，可降低患者脑水肿情况，降低血浆S100β表达，改善患者预后。[Objective] To explore the impact of ganglioside on plasma S100β in patients with progressive stroke and prognostic analysis. [Methods] Totally 76 patients with progressive stroke admitted to our hospital from Jan. 2011 to Dec. 2011 were randomly divided into treatment group and control group. Control group received conventional therapy. The treatment group was given monosialotetrahexosylganglioside sodium based on the therapy of control group. Plasma S100β, nerve injury score and excellent rate were compared between two groups. [Results] Plasma S100β in patients of treatment group 7d after treatment was significantly lower than those of control group（ P 〈0.05）. There was significant difference in nerve injury score 14d after treatment between two groups of patients（ P 〈0.05）. The excellence rate in patients of treatment group was 80% which was obviously higher than that in control group（80%）, and there was significant difference（ P 〈0.05）. [Conclusion] Monosia- lotetrahexosylganglioside sodium for the treatment of patients with progressive stroke can reduce cerebral edema, decrease plasma 810013 expression and improve the prognosis of the patients.

关 键 词：脑血管意外 血液 神经组织蛋白质S100 血液 神经节苷脂类 药理学 预后 

分 类 号：R743.3[医药卫生—神经病学与精神病学]